News

The study, conducted in 2022, highlights significant variations in glaucoma prevalence across different demographic groups, states, and counties.

In a paper presented at the American Academy of Ophthalmology annual meeting in Chicago, Jonathan Tan, a third year medical student at the Icahn School of Medicine at Mount Sinai detailed the study on ophthalmic eye drop waste in clinics, revealing 72% medication loss due to outdated 28-day expiration guidelines, resulting in significant financial waste. The study advocates following FDA expiration dates.

Michael Singer, MD, shared insights from his experience using a preservative-free, chloroprocaine ophthalmic gel as anesthesia for intravitreal injections and the results of research on the effectiveness of gel versus traditional drops.

According to OKYO Pharma, OK-101 is the first drug candidate to enroll patients specifically diagnosed with neuropathic corneal pain in a clinical trial. The Phase 2 trial is designed as a randomized, placebo-controlled, double-masked study to treat 48 NCP patients.

This year’s conference in Chicago showcased a diverse array of practice-changing data across multiple ophthalmic specialties, including advances in cataract surgery, glaucoma management, and retinal disease treatments.

In a presentation at the American Academy of Ophthalmology’s annual meeting in Chicago, T.Y. Alvin Lu, MD, a retina specialist at Johns Hopkins Medicine, discussed the application of large language models (LLMs) in revenue cycle management (RCM).

Jennifer Loh, MD, shared insights from on her presentation at the American Academy of Ophthalmology meeting in Chicago on the effects of CSF-1, which is the lowest effective concentration of pilocarpine approved in the United States.

At this year's American Academy of Ophthalmology (AAO) meeting, Jonathan Brugger, MD, spoke about the changing approach to epimacular membranes and the use of brilliant blue in the procedure.

Bonnie An Henderson, MD, highlights the importance of diverse learning methods and continuous education for clinicians in the Kelman Lecture.

The company will seek a strategic partner to continue development of APX3330, an oral small-molecule inhibitor of Ref-1 for the treatment of non-proliferative diabetic retinopathy.

Kamran Riaz, MD, discussed with the Eye Care Network a study on mitomycin intravascular chemoembolization for treating corneal neovascularization. The procedure showed promise, with a 70% success rate at 3 to 6 months, though patient selection is crucial. Some required multiple treatments, but overall outcomes are promising.

Acknowledging complex dynamics is an important part of traveling abroad as a doctor, according to University of Colorado ophthalmologist Michael Chen, MD, who helped develop an exercise to prepare trainees for the work overseas.

According to the company, its data replicate and expand upon the potential of ER-100 to improve retinal ganglion cell function and restore visual function in a nonhuman primate model of nonarteritic anterior ischemic optic neuropathy.

George O. Waring, IV, MD, provides insights from an on-demand poster as part of the annual American Academy of Ophthalmology taking place in Chicago, Illinois. This poster was titled, "Two-Year Clinical Feasibility Trial Outcomes for a Dual-Optic IOL System for the Treatment of Presbyopia and Cataract."

Alexander Fein, MD, spoke with the Eye Care Network to share how to approach a patient presenting with transient vision loss, what this type of vision loss can mean, and what additional testing might be needed to determine the best plan for care.

The retina is a key proving ground for long-held theories of genetics.

According to a study presented at the American Academy of Ophthalmology’s annual meeting in Chicago, investigational treatment reduced vision loss and protected key structures in the eye essential for vision.

Nathan Radcliffe, MD, shared insights from his presentation at the annual meeting of the American Academy of Ophthalmology entitled, "Early cataract extraction for angle closure glaucoma."

Meghan Berkenstock, MD, an associate professor of ophthalmology at the Wilmer Eye Institute, provides insights on paper from the uveitis free paper section of AAO 2024, about the use of TriNetX database to assess for the incidence and prevalence of both uveitis and its complications.

At this year's American Academy of Ophthalmology (AAO) meeting, John Berdahl, MD, spoke about the recent clinical trials of travoprost and its use in patients with prior SLT.

Custom-designed, lens-based surgery is a less interventional surgical option.

Christine Kay, MD sat down to discuss her presentation on gildeuretinol and its slowing of progression of Stargardt disease, studied in the TEASE program at this year's American Academy of Ophthalmology meeting held in Chicago, Illinois.

According to a presentation at the American Academy of Ophthalmology’s annual meeting in Chicago, a new study shows customized eyeglasses successfully addressed children’s complex eye needs.

Dr. Arepalli discussed a course focused on ocular conditions related to pregnancy and postpartum care, presented at the American Academy of Ophthalmology (AAO) meeting.

Christina Y Weng, MD, MBA sat down to discuss the Retina Ophthalmic Technology Assessment Symposium and her journal on teleretinal screening for diabetic eye disease at this year's American Academy of Ophthalmology meeting held in Chicago, Illinois.

George O. Waring, IV, MD provides insights from an on-demand poster as part of the annual American Academy of Ophthalmology taking place in Chicago, Illinois. This poster shared data on the the 9-month FDA data of the recently approved excimer laser, the TENEO laser, by Bausch + Lomb.

SLT superior to glaucoma drops as first-line treatment.

Adam Muzychuck, MD, FRCSC, sat down to discuss his presentation on the defocus curve performance of trifocal IOLs and the outcomes of the near activity vision questionnaire given to patients implanted with the Envy full range of vision IOL at this year's American Academy of Ophthalmology meeting held in Chicago, Illinois.

In data presented at the 128th annual meeting of the American Academy of Ophthalmology in Chicago, the two-year study finds patients with advanced disease can recover some vision.